The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

M.b. Stern - One of the best experts on this subject based on the ideXlab platform.

  • efficacy safety and tolerability of rasagiline as adjunctive therapy in elderly patients with parkinson s Disease
    European Journal of Neurology, 2012
    Co-Authors: Eduardo Tolosa, M.b. Stern
    Abstract:

    Background: Rasagiline, an MAO-B inhibitor, is indicated for the treatment of Parkinsons Disease (PD). In this post hoc analysis, the efficacy, safety and tolerability of rasagiline as an adjunct to levodopa were compared with placebo in elderly (‡70 years) and younger ( 0.1), and rasagiline was well tolerated amongst both groups of patients with a comparable incidence of total and dopaminergic AEs (P > 0.1). Conclusions: Adjunct rasagiline is efficacious and well tolerated in elderly nondemented patients (‡70 years) with moderate to advanced PD. Confirmation of the efficacy and safety of rasagiline in the elderly patient subgroup is especially relevant because of the increasing number of elderly patients with PD.

  • efficacy safety and tolerability of rasagiline as adjunctive therapy in elderly patients with parkinson s Disease
    European Journal of Neurology, 2012
    Co-Authors: Eduardo Tolosa, M.b. Stern
    Abstract:

    Background: Rasagiline, an MAO-B inhibitor, is indicated for the treatment of Parkinsons Disease (PD). In this post hoc analysis, the efficacy, safety and tolerability of rasagiline as an adjunct to levodopa were compared with placebo in elderly (‡70 years) and younger ( 0.1), and rasagiline was well tolerated amongst both groups of patients with a comparable incidence of total and dopaminergic AEs (P > 0.1). Conclusions: Adjunct rasagiline is efficacious and well tolerated in elderly nondemented patients (‡70 years) with moderate to advanced PD. Confirmation of the efficacy and safety of rasagiline in the elderly patient subgroup is especially relevant because of the increasing number of elderly patients with PD.

Marwan Hariz - One of the best experts on this subject based on the ideXlab platform.

Eduardo Tolosa - One of the best experts on this subject based on the ideXlab platform.

  • efficacy safety and tolerability of rasagiline as adjunctive therapy in elderly patients with parkinson s Disease
    European Journal of Neurology, 2012
    Co-Authors: Eduardo Tolosa, M.b. Stern
    Abstract:

    Background: Rasagiline, an MAO-B inhibitor, is indicated for the treatment of Parkinsons Disease (PD). In this post hoc analysis, the efficacy, safety and tolerability of rasagiline as an adjunct to levodopa were compared with placebo in elderly (‡70 years) and younger ( 0.1), and rasagiline was well tolerated amongst both groups of patients with a comparable incidence of total and dopaminergic AEs (P > 0.1). Conclusions: Adjunct rasagiline is efficacious and well tolerated in elderly nondemented patients (‡70 years) with moderate to advanced PD. Confirmation of the efficacy and safety of rasagiline in the elderly patient subgroup is especially relevant because of the increasing number of elderly patients with PD.

  • efficacy safety and tolerability of rasagiline as adjunctive therapy in elderly patients with parkinson s Disease
    European Journal of Neurology, 2012
    Co-Authors: Eduardo Tolosa, M.b. Stern
    Abstract:

    Background: Rasagiline, an MAO-B inhibitor, is indicated for the treatment of Parkinsons Disease (PD). In this post hoc analysis, the efficacy, safety and tolerability of rasagiline as an adjunct to levodopa were compared with placebo in elderly (‡70 years) and younger ( 0.1), and rasagiline was well tolerated amongst both groups of patients with a comparable incidence of total and dopaminergic AEs (P > 0.1). Conclusions: Adjunct rasagiline is efficacious and well tolerated in elderly nondemented patients (‡70 years) with moderate to advanced PD. Confirmation of the efficacy and safety of rasagiline in the elderly patient subgroup is especially relevant because of the increasing number of elderly patients with PD.

Jan Linder - One of the best experts on this subject based on the ideXlab platform.

Anders Fytagoridis - One of the best experts on this subject based on the ideXlab platform.